Immunoscore Refines CRC Prognosis, Therapy

Despite a strong evidence base, the assay has not been widely implemented in routine clinical practice.

1

The Immunoscore predicts colorectal cancer outcomes more accurately than standard TNM staging and guides treatment choices.
2

High Immunoscore patients with stage III microsatellite stable colorectal cancer benefit significantly from adjuvant chemotherapy.
3

Immunoscore refines risk stratification beyond MMR status, identifying high-risk subgroups within MSI-high tumors.
4

Immunoscore-IC, an expanded version, shows promise in identifying metastatic proficient-MMR CRC patients who may respond to immunotherapy.
5

Despite strong evidence, Immunoscore faces barriers to implementation in clinical practice, including cost and technical complexity.

1